A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.

Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...

Some people are microdosing certain weight loss drugs in an attempt to reap some of the drugs' benefits with fewer of their side effects. But doctors specializing in weight loss say that ...

Also in today’s edition: ‘no-show’ international student data and significant progress in Israel-Hamas ceasefire talks ...

CEO Dave Ricks said Monday that the company's weight-loss pill orforglipron could receive FDA approval as soon as early 2026. Read more here.

Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...

As the new year sparks a wave of weight loss resolutions and millions turn to weight loss medications, rising costs and the growing popularity of compounded alternatives have raised critical questions ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Compounding pharmacies make their own versions of weight loss drugs at a fraction of the price but there are some drawbacks.